The FDA has finalized its guidance on the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research special protocol assessments (SPA). SPA is a process in which product sponsors may ask to meet with FDA to reach an agreement on the design and size of clinical trials and clinical or animal studies to determine whether they adequately address the scientific and regulatory requirements to support eventual marketing approval.
The FDA has finalized its guidance on the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research special protocol assessments (SPAs). SPA is a process in which product sponsors may ask to meet with FDA to reach an agreement on the design and size of clinical trials and clinical or animal studies to determine whether they adequately address the scientific and regulatory requirements to support eventual marketing approval.
An SPA agreement indicates that the FDA concurs with the adequacy and acceptability of the overall protocol design, though it does not guarantee that the FDA will accept a New Drug Application or a Biologics License Application for the resulting proposed product, or that a marketing application will be approved.
The protocols that are eligible for SPA request are animal carcinogenicity protocols, drug substance and drug product stability protocols, animal efficacy protocols, protocols for trials intended to form the primary basis of an efficacy claim, and protocols needed for clinical studies to demonstrate biosimilarity or interchangeability of proposed biosimilar.
For proposed biosimilar products, protocols will only qualify for the SPA program if the sponsor has conducted a biosimilar biological product development (BPD) type 2 or type 3 meeting with the agency. The FDA says that “These detailed discussions are especially important if the development plan will include trial elements with which there is little past experience.”
If the product sponsor receives a letter indicating that no agreement with the agency has been reached, the sponsor can choose to initiate the trial without an agreement, respond in writing to the FDA to address the nonagreement letter without initiating the trial, or request a meeting to discuss the nonagreement letter.
An SPA agreement can be modified after testing begins if the FDA and the sponsor agree to a change in writing, and, in some cases, the FDA can rescind an SPA agreement (though the guidance notes that fewer than 1% of all SPA agreements have ever been rescinded).
BioRationality: Should mRNA Copies Be Filed as NDAs or Biosimilars?
November 4th 2024The article by Sarfaraz K. Niazi, PhD, argues that the FDA’s classification of future copies of messenger RNA (mRNA) products could be reconsidered, suggesting they might be eligible for new drug applications (NDAs) or a hybrid biosimilar category due to their unique characteristics and increasing prevalence.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf
October 25th 2024At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.